[Clinical experiences with psilocybin (CY39 Sandoz)].
No abstract is available for this record.
Bibliographic context
- Journal
- Unknown
- Date
- 1960-12-31
- Source
- Europe PMC
- DOI
- Unavailable
- PubMed
- 13910754
Topics and keywords
Citation graph
0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.
Related papers
Contribution of the Serotonin 5-HT2A Receptor to the Therapeutic Effect of Psilocin on Social Behavior Deficits in Mice Repeatedly Exposed to Social Defeat StressNeuropsychopharmacology Reports · 2026-08-31Psilocybin reduces fear memory and restores neuroplasticity in the hippocampus and medial prefrontal cortex.Journal of Psychopharmacology · 2026-06-27Blocking 5-HT2B receptors abolishes psilocybin’s efficacy in the rat forced swim testJournal of Psychopharmacology · 2026-06-22Psilocybin-assisted therapy in treatment-resistant depression: rapid remission, uncertain durability, and the next phase of clinical evidenceAnnals of Medicine and Surgery · 2026-06-17Psilocybin and Mental Health Outcomes: Scoping Review with ☸SAIMSARASAIMSARA Journal · 2026-06-14Efficacy of Psilocybin-Assisted Therapy in Major Depressive Disorder: A Systematic Review and Meta-AnalysisPsychiatry International · 2026-06-14Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depressionJournal of Affective Disorders · 2026-06-03Psilocybin shows rapid relief for depression symptomsMental Health Weekly · 2026-05-28